What is a stock summary page? Click here for an overview.
Business Description
TScan Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US89854M1018
Description
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.98 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | -0.81 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.22 | |||||
| Beneish M-Score | -4.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -69.4 | |||||
| 3-Year EBITDA Growth Rate | 35 | |||||
| 3-Year EPS without NRI Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 41.2 | |||||
| 3-Year Book Growth Rate | -14.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 78.08 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.58 | |||||
| 9-Day RSI | 33.51 | |||||
| 14-Day RSI | 34.72 | |||||
| 3-1 Month Momentum % | -28.07 | |||||
| 6-1 Month Momentum % | -64.29 | |||||
| 12-1 Month Momentum % | -69.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.14 | |||||
| Quick Ratio | 8.14 | |||||
| Cash Ratio | 8.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.3 | |||||
| Shareholder Yield % | -37.49 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4787.68 | |||||
| Net Margin % | -4527.66 | |||||
| FCF Margin % | -4071.27 | |||||
| ROE % | -63.81 | |||||
| ROA % | -39.67 | |||||
| ROIC % | -135.39 | |||||
| 3-Year ROIIC % | -137.98 | |||||
| ROC (Joel Greenblatt) % | -177.97 | |||||
| ROCE % | -42.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 67.88 | |||||
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.41 | |||||
| EV-to-EBIT | 0.74 | |||||
| EV-to-Forward-EBIT | -0.43 | |||||
| EV-to-EBITDA | 0.76 | |||||
| EV-to-Revenue | -32.47 | |||||
| EV-to-Forward-Revenue | 23.06 | |||||
| EV-to-FCF | 0.8 | |||||
| Price-to-GF-Value | 10.24 | |||||
| Price-to-Net-Current-Asset-Value | 0.61 | |||||
| Price-to-Net-Cash | 0.61 | |||||
| Earnings Yield (Greenblatt) % | 135.14 | |||||
| FCF Yield % | -116.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TScan Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.816 | ||
| EPS (TTM) ($) | -1.15 | ||
| Beta | 1.16 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 64.47 | ||
| 14-Day RSI | 34.72 | ||
| 14-Day ATR ($) | 0.173684 | ||
| 20-Day SMA ($) | 1.97825 | ||
| 12-1 Month Momentum % | -69.81 | ||
| 52-Week Range ($) | 1.711 - 9.69 | ||
| Shares Outstanding (Mil) | 56.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TScan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TScan Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TScan Therapeutics Inc Frequently Asked Questions
What is TScan Therapeutics Inc(TCRX)'s stock price today?
The current price of TCRX is $1.74. The 52 week high of TCRX is $9.69 and 52 week low is $1.71.
When is next earnings date of TScan Therapeutics Inc(TCRX)?
The next earnings date of TScan Therapeutics Inc(TCRX) is 2025-05-13 Est..
Does TScan Therapeutics Inc(TCRX) pay dividends? If so, how much?
TScan Therapeutics Inc(TCRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers